Get started
Author

Kirk Szafranski

Observed names: K Szafranski, K. Szafranski, KIRK SZAFRANSKI, Kirk J. Szafranski
Institution: EVERSANA (Canada)
OpenAlex ID: A5089042196
The burden of osteoporosis in four Latin American countries: Brazil, Mexico, Colombia, and Argentina
2019 · Rima Aziziyeh, Mo Amin, et al. · Journal of Medical Economics · 128
PDF
Non-coding RNA in neural function, disease, and aging
2015 · Kirk Szafranski · Frontiers in Genetics · 86
PDF
Roles for Pbp1 and Caloric Restriction in Genome and Lifespan Maintenance via Suppression of RNA-DNA Hybrids
2014 · Jayesh S. Salvi, Janet N.Y. Chan, et al. · Developmental Cell · 63
PDF
The fine line between lifespan extension and shortening in response to caloric restriction
2014 · Kirk Szafranski, Karim Mekhail · Nucleus · 33
PDF
Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: A microsimulation model and cost-effectiveness analysis from a US perspective with relevance to Medicaid
2024 · Jerry Frank, Daniel Son, et al. · Journal of Managed Care & Specialty Pharmacy · 20
PDF
Cost–utility analysis of a flash continuous glucose monitoring system in the management of people with type 2 diabetes mellitus on basal insulin therapy—An Italian healthcare system perspective
2024 · Stefano Del Prato, Francesco Giorgino, et al. · Diabetes Obesity and Metabolism · 17
PDF
Benefits of fracture liaison services (FLS) in four Latin American countries: Brazil, Mexico, Colombia, and Argentina
2020 · Rima Aziziyeh, Javier Garcia Perlaza, et al. · Journal of Medical Economics · 15
Conserved Pbp1/Ataxin-2 regulates retrotransposon activity and connects polyglutamine expansion-driven protein aggregation to lifespan-controlling rDNA repeats
2018 · Lauren A. Ostrowski, Amanda C. Hall, et al. · Communications Biology · 14
PDF
Cost-Effectiveness of FreeStyle Libre for Glucose Self-Management Among People with Diabetes Mellitus: A Canadian Private Payer Perspective
2024 · Stewart Harris, Sal Cimino, et al. · Diabetes Therapy · 13
PDF
The Determination of Diabetes Utilities, Costs, and Effects Model: A Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes: Comparative Validation
2024 · Kirk Szafranski, Gerard De Pouvourville, et al. · Value in Health · 13
Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half‐life factor IX therapies for severe or moderately severe haemophilia B
2023 · Robert Klamroth, Ashley Bonner, et al. · Haemophilia · 6
PDF
1051-P: Cost-Effectiveness of Flash CGM Compared with SMBG—A Canadian Private-Payer Perspective
2024 · STEWART B. HARRIS, SAL CIMINO, et al. · Diabetes · 3
P45 Internal, External, and Cross-Validation of the DEDUCE Model, a Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes
2022 · J Coaquira Castro, G De Pouvourville, et al. · Value in Health · 2
PDF
Cost-effectiveness of Freestyle Libre Systems for People with Type 2 Diabetes Mellitus on Basal Insulin Therapy in the Netherlands: An Economic Evaluation from a Societal Perspective Within a Publicly Funded Healthcare System
2025 · Peter van Dijk, Chris Chesters, et al. · Diabetes Therapy · 1
PDF
PND2 Indirect Treatment Comparisons of Apomorphine Sublingual Film Versus Apomorphine Subcutaneous Injection for the on-Demand Treatment of "Off" Episodes in Patients with Parkinson's Disease
2020 · N. Lenton, S. Singh, et al. · Value in Health · 1
Ee434 Development of a Cost Utility Model to Assess the Incremental Cost Effectiveness of Continuous Dual Glucose Ketone Monitoring System Versus Continuous Glucose Monitoring System in People With Diabetes
2026 · Johan Jendle, Mark Moses, et al. · Value in Health
Ee232 Cost-effectiveness of Lenacapavir Versus Oral and Injectable Prep Options for Hiv Prevention in the United States
2026 · JEANPIERRE COAQUIRA CASTRO, David Cameron, et al. · Value in Health
Tislelizumab efficacy and safety compared to other anti–PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma
2026 · Jaffer A. Ajani, Elizabeth Smyth, et al. · Frontiers in Immunology
PDF
EE326 Development and Validation of a Novel Patient Microsimulation Cost-Effectiveness Model to Evaluate Automated Insulin Delivery Systems in Type 2 Diabetes
2025 · Joshua Weinstein, Colin Hopley, et al. · Value in Health
EE682 Targeted Literature Review Informing Economic Model Structures in Atherosclerotic Cardiovascular Disease
2025 · Luiz Causin, Kirk Szafranski, et al. · Value in Health
EE208 Cost-Effectiveness Analysis of Intermittently Scanned Continuous Glucose Monitoring in Individuals With Type 2 Diabetes Using Insulin in Sweden: A National Real-World Evidence Perspective
2025 · David Nathanson, Jan Bolinder, et al. · Value in Health
EE207 Cost-Effectiveness Analysis of Intermittently Scanned Continuous Glucose Monitoring in Individuals With Type 1 Diabetes in Sweden: A National Real-World Evidence Perspective
2025 · Katarina Eeg-Olofsson, Jan Bolinder, et al. · Value in Health
EE200 Cost-Effectiveness Analysis of FreeStyle Libre Systems vs. Self-Monitoring of Blood Glucose in People With Type 2 Diabetes on Basal Insulin: An Israeli Healthcare System Perspective
2025 · Dan Greenberg, Jack Timmons, et al. · Value in Health
Author response for "Cost–utility analysis of a flash continuous glucose monitoring system in the management of people with type 2 diabetes mellitus on basal insulin therapy—An Italian healthcare system perspective"
2024 · Stefano Del Prato, Francesco Giorgino, et al. · Publons reviews and discussion
MSR50 A Practical Method for Determining the Optimal Allocation between Computation Time and Accuracy in Probabilistic Patient-Level Microsimulation Models
2023 · K. Szafranski, T. Disher, et al. · Value in Health
PDF
Works count: 27
Citation count: 415
H-index: 10
I10-index: 10
Year
Topic
Type